Pathophysiology of insulin resistance

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 20, Issue 4, 2006, Pages 665-679

  Sesti, Giorgio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

glucose transport; insulin resistance; insulin signalling

Indexed keywords

ACETYL COENZYME A; CASEIN KINASE II; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; LIPID; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C LAMBDA; PROTEIN KINASE C ZETA; PROTEIN SERINE KINASE; PROTEIN TYROSINE PHOSPHATASE;

CLINICAL FEATURE; DYSLIPIDEMIA; ENZYME ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN MUSCLE LEVEL; GLYCOGEN SYNTHESIS; HORMONE ACTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CYTOKINES; FATTY ACIDS; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; GLYCOGEN; HUMANS; INSULIN; INSULIN RESISTANCE; MUSCLES; PHOSPHORIC DIESTER HYDROLASES; PROTEIN KINASE C; PROTEIN-TYROSINE-PHOSPHATASE; PROTO-ONCOGENE PROTEINS C-AKT; PYROPHOSPHATASES; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 33845244172     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2006.09.007     Document Type: Review

References (99)

1. DeFronzo R.A. The triumvirate: β-cell, muscle or liver. A collusion responsible for NIDDM. Diabetes 37 (1988) 667-687
2. Shulman G.I. Cellular mechanisms of insulin resistance. The Journal of Clinical Investigation 106 (2000) 171-176
3. DeFronzo R.A., Tobin J.D., and Anders R. Glucose clamp technique: a model for quantifying insulin secretion and resistance. The American Journal of Physiology 237 (1979) E214-E223
4. Shulman G.I., Rothman D.L., Jue T., et al. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. The New England Journal of Medicine 322 (1990) 223-228
5. Bogardus C., Lillioja S., Stone K., et al. Correlation between muscle glycogen synthase activity and in vivo insulin action in man. The Journal of Clinical Investigation 73 (1984) 1185-1190
6. Roden M., Petersen K.F., and Shulman G.I. Nuclear magnetic resonance studies of hepatic glucose metabolism in humans. Recent Progress in Hormone Research 56 (2001) 219-237
7. Damsbo P., Vaag A., Hother-Nielsen O., et al. Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 34 (1991) 239-245
8. Kelley D.E., Mintun M.A., Watkins S.C., et al. The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. The Journal of Clinical Investigation 97 (1996) 2705-2713
9. Rothman D.L., Shulman R.G., and Shulman G.I. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. The Journal of Clinical Investigation 89 (1992) 1069-1075
10. Zierath J.R., He L., Guma A., et al. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 39 (1996) 1180-1189
11. Dohm G.L., Tapscott E.B., Pories W.J., et al. An in vitro human muscle preparation suitable for metabolic studies. Decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects. The Journal of Clinical Investigation 82 (1988) 486-494
12. Eriksson J., Koranyi L., Bourey R., et al. Insulin resistance in Type II (non-insulin-dependent) diabetic patients and their relatives is not associated with a defect in the expression of the insulin-responsive glucose transporter (GLUT4) gene in human skeletal muscle. Diabetologia 35 (1992) 143-147
13. Rothman D.L., Magnusson I., Cline G., et al. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proceedings of the National Academy of Sciences of the USA 92 (1995) 983-987
14. Braithwaite S.S., Palazuk B., Colca J.R., et al. Reduced expression of hexokinase II in insulin-resistant diabetes. Diabetes 44 (1995) 43-48
15. Kruszynska Y.T., Mulford M.I., Baloga J., et al. Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects. Diabetes 47 (1998) 1107-1113
16. Cline G.W., Petersen K.F., Krssak M., et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. The New England Journal of Medicine 341 (1999) 240-246
17. Unger R.H., and Orci L. Lipotoxic diseases of nonadipose tissues in obesity. International Journal of Obesity and Related Metabolic Disorders 24 supplement 4 (2000) S28-S32
18. Jacob S., Machann J., Rett K., et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 48 (1999) 1113-1119
19. Petersen K.F., Hendler R., Price T., et al. 3C/31P NMR studies on the mechanism of insulin resistance in obesity. Diabetes 47 (1998) 381-386
20. Randle P.J., Garland P.B., Hales C.N., et al. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1 (1963) 785-789
21. Roden M., Price T.B., Perseghin G., et al. Mechanism of free fatty acid-induced insulin resistance in humans. The Journal of Clinical Investigation 97 (1996) 2859-2865
22. Dresner A., Laurent D., Marcucci M., et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. The Journal of Clinical Investigation 103 (1999) 253-259
23. Gumà A., Zierath J.R., Wallberg-Henriksson H., et al. Insulin induces translocation of GLUT-4 glucose transporters in human skeletal muscle. The American Journal of Physiology 268 (1995) E613-E622
24. James D.E., Strube M.M., and Mueckler M.M. Molecular cloning and characterization of an insulin-regulatable glucose transporter. Nature 338 (1989) 83-87
25. Charron M.J., Brosius F.C., Alper S.L., et al. A glucose transport protein expressed predominately in insulin-sensitive tissues. Proceedings of the National Academy of Sciences of the USA 86 (1989) 2535-2539
26. Birnbaum M.J. Identification of a novel gene encoding an insulin-responsive glucose transporter protein. Cell 57 (1989) 305-315
27. Shepherd P.R., and Khan B.B. Glucose transporters and insulin action. The New England Journal of Medicine 341 (1999) 248-2257
28. Zierath J.R., Krook A., and Wallberg-Henriksson H. Insulin action and insulin resistance in human skeletal muscle. Diabetologia 43 (2000) 821-835
29. Sun X.J., Rothenberg P., Kahn C.R., et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352 (1991) 73-77
30. Sun X.J., Wang L.M., Zhang Y., et al. Role of IRS-2 in insulin and cytokine signalling. Nature 377 (1995) 173-177
31. Sesti G., Federici M., Hribal M.L., et al. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J 15 (2001) 2099-2111
32. Saltiel A.R., and Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414 (2001) 799-806
33. White M.F. IRS proteins and the common path to diabetes. American Journal of Physiology. Endocrinology and Metabolism 283 (2001) E413-E422
34. Czech M.P., and Corvera S. Signaling mechanisms that regulate glucose transport. The Journal of Biological Chemistry 274 (1999) 1865-1868
35. Farese R.V. Function and dysfunction of aPKC isoforms for glucose transport in insulin-sensitive and insulin-resistant states. American Journal of Physiology. Endocrinology and Metabolism 283 (2002) E1-E11
36. Kane S., Sano H., Liu S.C.H., et al. A method to identify serine kinase substrates: Akt phosphorylates a novel adipocyte protein with a Rab GTPase-activating protein (GAP) domain. The Journal of Biological Chemistry 277 (2002) 22115-22118
37. Sano H., Kane S., Sano E., et al. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. The Journal of Biological Chemistry 278 (2003) 14599-14602
38. Ullrich A., Bell R.J., Chen E.Y., et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313 (1985) 756-761
39. Ebina Y., Ellis L., Jarnagin K., et al. The structural basis for hormone-activated transmembrane signalling. Cell 40 (1985) 747-758
40. Ullrich A., Gray A., Tam A.W., et al. Insulin-like growth factor I receptor primary structure: comparision with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5 (1986) 2503-2512
41. Shier P., and Watt V.M. Primary structure of a putative receptor for a ligand of the insulin family. The Journal of Biological Chemistry 264 (1989) 14605-14668
42. Sesti G., Federici M., Lauro D., et al. Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms. Diabetes/Metabolism Research and Reviews 17 (2001) 363-373
43. Mosthaf L., Grako D., Dull T.J., et al. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J 9 (1990) 2409-2413
44. Yamaguchi Y., Flier J.S., Yokota A., et al. Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese hamster ovary cells. Endocrinology 129 (1991) 2058-2066
45. McClain D.A. Different ligand affinities of the two human insulin receptor splice variants are reflected in parallel changes in sensitivity for insulin action. Molecular Endocrinology 5 (1991) 734-739
46. Yamaguchi Y., Flier J.S., Benecke H., et al. Ligand-binding properties of the two isoforms of the human insulin receptor. Endocrinology 132 (1993) 1132-1138
47. Leibiger B., Leibiger I.B., Moede T., et al. Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic β cells. Molecular Cell 7 (2001) 559-570
48. Sesti G., Marini M.A., Montemurro A., et al. Evidence that two naturally occurring human insulin receptor α-subunit variants are immunologically distinct. Diabetes 41 (1992) 6-11
49. Sesti G., Tullio A.N., D'Alfonso R., et al. Tissue-specific expression of two alternatively spliced isoforms of the human insulin receptor protein. Acta Diabetologica 31 (1994) 59-65
50. Norgren S., Zierath J., Wedell A., et al. Regulation of human insulin receptor RNA splicing in vivo. Proceedings of the National Academy of Sciences of the USA 91 (1994) 1465-1469
51. Sesti G., D'Alfonso R., Vargas Punti M.D., et al. Peptide-based radioimmunoassay for the two isoforms of the human insulin receptor. Diabetologia 38 (1995) 445-453
52. Sell S.M., Reese D., and Ossowski V.M. Insulin-inducible changes in insulin receptor mRNA splice variants. The Journal of Biological Chemistry 269 (1994) 30769-30772
53. Mosthaf L., Vogt B., Haring H.U., et al. Altered expression of insulin receptor types A and B in the skeletal muscle of non-insulin-dependent diabetes mellitus. Proceedings of the National Academy of Sciences of the USA 88 (1991) 4728-4730
54. Mosthaf L., Eriksson J., Haring H.U., et al. Insulin receptor isotypes expression correlates with risk of non-insulin-dependent diabetes mellitus. Proceedings of the National Academy of Sciences of the USA 90 (1993) 2633-2635
55. Norgren S., Zierath J., Galuska D., et al. Differences in the ratio of RNA encoding two isoforms of the insulin receptor between control and NIDDM patients. Diabetes 42 (1993) 675-681
56. Benecke H., Flier J.S., and Moller D.E. Alternatively spliced variants of the human insulin receptor protein. The Journal of Clinical Investigation 89 (1992) 2066-2070
57. Anderson C.M., Henry R.R., Knudson P.E., et al. Relative expression of insulin receptor isoforms does not differ in lean, obese, and noninsulin-dependent diabetes mellitus subjects. The Journal of Clinical Endocrinology and Metabolism 72 (1993) 1380-1383
58. Hansen T., Bjorbaek C., Vestergaard H., et al. Expression of insulin receptor spliced variants and their functional correlates in muscle from patients with non-insulin-dependent diabetes mellitus. The Journal of Clinical Endocrinology and Metabolism 77 (1993) 1500-1505
59. Sesti G., Marini M.A., Tullio A.N., et al. Altered expression of the two naturally occurring human insulin receptor variants in isolated adipocytes of non-insulin-dependent diabetes mellitus patients. Biochemical and Biophysical Research Communications 181 (1991) 1419-1424
60. Kellerer M., Sesti G., Seffer E., et al. Altered pattern of insulin receptor isotypes in skeletal muscle membranes of Type II (non-insulin-dependent) diabetic subjects. Diabetologia 36 (1993) 628-632
61. Federici M., Porzio O., Zucaro L., et al. Distribution of insulin/insulin-like growth factor-I hybrid receptors in human tissues. Molecular and Cellular Endocrinology 129 (1997) 121-126
62. Soos M.A., Field C.E., and Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. The Biochemical Journal 290 (1993) 419-426
63. Seely B.L., Reichart D.R., Takata Y., et al. A functional assessment of insulin/Insulin-like Growth Factor-I hybrid receptors. Endocrinology 136 (1995) 1635-1641
64. Federici M., Zucaro L., Porzio O., et al. Increased expression of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of non-insulin-dependent diabetes mellitus subjects. The Journal of Clinical Investigation 98 (1996) 2887-2893
65. Federici M., Porzio O., Zucaro L., et al. Increased abundance of insulin/IGF-I hybrid receptors in adipose tissue from NIDDM patients. Molecular and Cellular Endocrinology 135 (1997) 41-47
66. Federici M., Porzio O., Lauro D., et al. Increased abundance of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of obese subjects is correlated with in vivo insulin sensitivity. The Journal of Clinical Endocrinology and Metabolism 83 (1998) 2911-2915
67. Federici M., Lauro D., D'Adamo M., et al. Expression of insulin/IGF-I hybrid receptors is increased in skeletal muscle of patients with chronic primary hyperinsulinemia. Diabetes 47 (1998) 87-92
68. Spampinato D., Pandini G., Iuppa A., et al. Insulin/insulin-like growth factor-I hybrid receptors overexpression is not an early defect in insulin-resistant subjects. The Journal of Clinical Endocrinology and Metabolism 85 (2000) 4219-4223
69. Cusi K., and DeFronzo R. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. The Journal of Clinical Endocrinology and Metabolism 85 (2000) 3077-3084
70. Caro J.F., Sinha M.K., Raju S.M., et al. Insulin receptor kinase in human skeletal muscle from obese subjects with and without Noninsulin Dependent Diabetes. The Journal of Clinical Investigation 79 (1987) 1330-1337
71. Goodyear L.J., Giorgino F., Sherman L.A., et al. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. The Journal of Clinical Investigation 95 (1995) 2195-2204
72. Nolan J.J., Freidenberg G., Henery R., et al. Role of human skeletal muscle insulin receptor kinase in the in vivo insulin resistance of noninsulin-dependent diabetes mellitus and obesity. The Journal of Clinical Endocrinology and Metabolism 78 (1994) 471-477
73. Arner P., Pollare T., Lithell H., et al. Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and Type II (non-insulin-dependent) diabetes mellitus. Diabetologia 30 (1987) 437-440
74. Maegawa H., Shigeta Y., Egawa K., et al. Impaired autophosphorylation of insulin receptors from abdominal skeletal muscles in nonobese subjects with NIDDM. Diabetes 40 (1991) 815-819
75. Sinha M.K., Pories W.J., Flickinger E.G., et al. Insulin-receptor kinase activity of adipose tissue from morbidly obese humans with and without NIDDM. Diabetes 36 (1987) 620-625
76. Caro J.F., Ittoop O., Pories W.J., et al. Studies on the mechanism of insulin resistance in the liver from humans with noninsulin-dependent diabetes. Insulin action and binding in isolated hepatocytes, insulin receptor structure, and kinase activity. The Journal of Clinical Investigation 78 (1986) 249-258
77. Brozinick Jr. J.T., Roberts B.R., and Dohm G.L. Defective Signaling Through Akt-2 and -3 But Not Akt-1 in Insulin-Resistant Human Skeletal Muscle Potential Role in Insulin Resistance. Diabetes 52 (2003) 935-941
78. Kim Y.B., Nikoulina S.E., Ciaraldi T.P., et al. Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. The Journal of Clinical Investigation 104 (1999) 733-741
79. Björnholm M., Kawano Y., Lehtihet M., et al. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity are decreased in skeletal muscle from NIDDM subjects following in vivo insulin stimulation. Diabetes 46 (1997) 524-527
80. Krook A., Bjornholm M., Galuska D., et al. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 49 (2000) 284-292
81. Smith U., Axelsen M., Carvalho E., et al. Insulin signaling and action in fat cells: association with insulin resistance and type 2 diabetes. Annals of the New York Academy of Sciences 892 (1999) 119-126
82. Krook A., Roth R.A., Jiang X.J., et al. Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from non-insulin-dependent diabetic subjects. Diabetes 47 (1998) 1281-1286
83. Beeson M., Sajan M.P., Dizon M., et al. Activation of protein kinase C-ζ by insulin and phosphatidylinositol-3, 4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance. Amelioration by rosiglitazone and exercise. Diabetes 52 (2003) 1926-1934
84. Kim Y.-B., Kotani K., Ciaraldi T.P., et al. Insulin-stimulated PKC- ζ /λ activity is reduced and PDK-1 activity is normal in muscle of insulin-resistant humans. Diabetes 52 (2003) 1935-1942
85. Sajan M.P., Standaert M.L., Bandyopadhyay G., et al. Impaired activation of protein kinase C-ζ by insulin and phosphatidylinositol-3,4,5-(PO4)3 is cultured preadipocyte-derived adipocytes and myotubes of obese subjects. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 3994-3998
86. Garvey W.T., Maianu L., Zhu J.H., et al. Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. The Journal of Clinical Investigation 101 (1998) 2377-2386
87. Dohm G.L., Elton C.W., Friedman J.E., et al. Decreased expression of glucose transporters in muscle from insulin-resistant patients. The American Journal of Physiology 260 (1991) E459-E463
88. Handberg A., Vaag A., Damsbo P., et al. Expression of insulin-regulatable glucose transporters in skeletal muscle from Type II (non-insulin-dependent) diabetic patients. Diabetologia 33 (1990) 625-627
89. Ahmad F., Considine R.V., and Goldstein B.J. Increased abundance of the receptor-type protein-tyrosine phosphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects. The Journal of Clinical Investigation 95 (1995) 2806-2812
90. Ahmad F., Azevedo J.L., Cortright R., et al. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. The Journal of Clinical Investigation 100 (1997) 449-458
91. Ahmad F., Considine R.V., Bauer T.L., et al. Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue. Metabolism 46 (1997) 1140-1145
92. Goldfine I.D., Maddux B.A., Youngren J.F., et al. Role of PC-1 in the etiology of insulin resistance. Annals of the New York Academy of Sciences 892 (1999) 204-222
93. Youngren J.F., Maddux B.A., Sasson S., et al. Skeletal muscle content of membrane glycoprotein PC-1 in obesity. Relationship to muscle glucose transport. Diabetes 45 (1996) 1324-1328
94. Frittitta L., Youngren J.F., Sbraccia P., et al. Increased adipose tissue PC-1 protein content, but not tumour necrosis factor-alpha gene expression, is associated with a reduction of both whole body insulin sensitivity and insulin receptor tyrosine-kinase activity. Diabetologia 40 (1997) 282-289
95. Pickup J.C., Mattock M.B., Chusney G.D., et al. Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabetes. Diabetes Care 27 (2004) 813-823
96. Kern P.A., Ranganathan S., Li C., et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. American Journal of Physiology. Endocrinology and Metabolism 280 (2001) E745-E751
97. Hotamisligil G.S., Peraldi P., Budavari A., et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271 (1996) 665-668
98. Carlson C.J., Koterski S., Sciotti R.J., et al. Enhanced basal activation of mitogen-activated protein kinases in adipocytes from type 2 diabetes: potential role of p38 in the downregulation of GLUT4 expression. Diabetes 52 (2003) 634-641
99. Bouzakri K., Roques M., Gual P., et al. Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. Diabetes 52 (2003) 1319-1325